Separated proliferative microglial cells, preparation method thereof and application of separated proliferative microglial cells in replacement of microglial cells
A technology of microglia and macrophages, applied in the field of microglia and their preparation, can solve the problems of weakening the proliferation ability of microglia and myeloid cells in the host CNS, and achieves omitting myeloablative treatment, Improve competitive advantage and reduce risk
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2022-06-03
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
Technical field
[0001] The present invention belongs to the field of biological drugs, specifically relates to an isolated relative endogenous microglia has a competitive advantage of microglia and preparation method thereof. Background
[0002] Microglia are important immune cells in the central nervous system (CNS), and microglia carrying genetic mutations are involved in the occurrence and development of a variety of neurodegenerative lesions. For example, 50% of the currently known genomic risk sites for Alzheimer's disease are expressed in microglia >. Therefore, replacing diseased microglia, or enhancing microglia function, has great clinical application prospects. Conventional gene therapy ideas cannot be used for microglia, mainly due to: 1. Commonly used non-integrative viral vectors (such as AAV) cannot infect microglia; 2. Integrative viral vectors (such as lentivirus) can infect microglia, but they can only affect the cells locally at the injection site, and cannot...
Examples
Embodiment 1
[0072] 1) Medullary cell proliferation in the central nervous system of wild-type mice with non-lethal dose irradiation and / or demineralizing drug busulfan, while macrophage colony factor 1 receptor inhibitors are used to remove endogenous microglia in the host central nervous system;
[0073] 2) Give other wild-type mouse donors other than wild-type mouse hosts with macrophage colony factor 1 receptor inhibitors, and obtain proliferative microglia from the donor on the 3-5th day after the cessation of macrophage colony factor 1 receptor inhibitors; And in step 1) the central nervous system of the treated host is inhibited by myeloid cells and microglia, more than 95% of the host microglia are eliminated with the drug, and within 24 to 48 hours after withdrawal, proliferative microglia are implanted;
[0074] 3) Give the host bone marrow cells or hematopoietic stem cells; Myeloid cells produced by said bone marrow cells or hematopoietic stem cells are able to be eliminated by his ...